By Karen Roman
SkylineDx said its Merlin CP-GEP molecular test is uniquely recognized by the National Comprehensive Cancer Network (NCCN) for predictive use in select T1 and T2 melanoma patients.
The test provides informed risk stratification and helps physicians better understand metastatic risk beyond traditional features, the company stated.
“NCCN’s recognition of Merlin CP-GEP reflects the importance of using rigorously validated, predictive tests to better understand metastatic potential and support more informed clinical management,” said Dharminder Chahal, SkylineDx’s CEO.
READ MORE
IPO Edge NYSE Firesides Scheduled for March 20 & June 2
Never Miss our Weekly Highlights HERE
